LivaNova
LIVN
75.93
+1.00
+1.33%
LivaNova
US · LIVN
#2263 by market cap
Listed 1970
75.93
+1.00
+1.33%
Live - 5344 symbols - heartbeat 52s ago
· 2026-10-08 02:49
After-hours
75.93
0.00%
Overnight
75.93
0.00%
- Market cap
- 4.18B
- P/E (TTM)i
- 22.40
- P/Bi
- 3.16
- EPSi
- -4.45
- Div yieldi
- 0.00%
- 52W posi
- 73%
Reader sentiment
Are you bullish or bearish on LIVN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.1 percentage points.
Institutional ownership
- Held by institutions
- 114.78% -0.11pp
- Institutions
- 374 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund95.55%
Hedge Fund10.30%
Public Company4.48%
Government Pension Fund1.90%
Insurance Company1.47%
Private Company0.47%
Individual/Insider0.44%
Sovereign Wealth Fund0.31%
Family Office/Trust0.17%
Top holders as of 2026-06-30
BlackRock
13.73% · 7.57M sh
PRIMECAP Management Company
7.57% · 4.17M sh
FMR
5.71% · 3.15M sh
Hood River Capital Management LLC
4.66% · 2.57M sh
AQR Capital Management
4.25% · 2.34M sh
Artisan Partners Limited Partnership
4.04% · 2.22M sh
State Street Global Advisors
3.93% · 2.17M sh
American Century Investment Management
3.66% · 2.01M sh
Dimensional Fund Advisors
3.35% · 1.85M sh
Geode Capital Management, LLC
3.19% · 1.76M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 19 sells
| Name | Role | Stake |
|---|---|---|
| Alex Shvartsburg | Chief Financial Officer | 0.08% |
| William Kozy | Chairman of Board & Interim CEO | 0.07% |
| Stephanie Bolton | President of Global Epilepsy | 0.04% |
| Trui Hebbelinck | Chief Human Resources Officer | 0.03% |
| Stacy Seng | Independent Non-Executive Director | 0.03% |
| Vladimir Makatsaria | Chief Executive Officer | 0.03% |
| Todd Schermerhorn | Independent Non-Executive Director | 0.02% |
| Sharon O'Kane | Independent Non-Executive Director | 0.02% |
| Franco Poletti | President of Cardiopulmonary Business Unit | 0.02% |
| Peter Wilver | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Anne Liddy | Chief Legal Officer | Other Derivative Acquisition | +6,291 | -- |
| 2026-09-09 | Francesco Bianchi | Independent Non-Executive Director | Open Market Disposition | -3,500 | $78.01 |
| 2026-09-03 | Brooke Story | Independent Director | Open Market Disposition | -2,300 | $81.42 |
| 2026-09-01 | Franco Poletti | President of Cardiopulmonary Business Unit | Intent to Sell (Form 144) | -10,755 | $82.09 |
| 2026-08-30 | Francesco Bianchi | Independent Non-Executive Director | Open Market Disposition | -1,650 | $79.72 |
| 2026-08-10 | Ahmet Tezel | Chief Innovation Officer | Derivative Exercise and Sale | -12,692 | $52.68–77.86 |
| 2026-06-14 | Todd Schermerhorn | Independent Non-Executive Director | Derivative Exercise and Sale | -486 | $79.70 |
| 2026-06-14 | Todd Schermerhorn | Independent Non-Executive Director | Other Derivative Acquisition | +2,383 | -- |
| 2026-06-14 | Todd Schermerhorn | Independent Non-Executive Director | Derivative Exercise and Retained | +3,556 | -- |
| 2026-06-14 | Peter Wilver | Independent Director | Derivative Exercise and Sale | -486 | $79.70 |
| 2026-06-14 | Peter Wilver | Independent Director | Other Derivative Acquisition | +2,383 | -- |
| 2026-06-14 | Peter Wilver | Independent Director | Derivative Exercise and Retained | +3,556 | -- |
| 2026-06-14 | William Kozy | Chairman of Board & Interim CEO | Derivative Exercise and Sale | -682 | $79.70 |
| 2026-06-14 | William Kozy | Chairman of Board & Interim CEO | Other Derivative Acquisition | +2,383 | -- |
| 2026-06-14 | William Kozy | Chairman of Board & Interim CEO | Derivative Exercise and Retained | +4,999 | -- |
| 2026-06-14 | Stacy Seng | Independent Non-Executive Director | Derivative Exercise and Sale | -486 | $79.70 |
| 2026-06-14 | Stacy Seng | Independent Non-Executive Director | Other Derivative Acquisition | +2,383 | -- |
| 2026-06-14 | Stacy Seng | Independent Non-Executive Director | Derivative Exercise and Retained | +3,556 | -- |
| 2026-06-14 | Donald Zurbay | Director | Derivative Exercise and Sale | -308 | $79.70 |
| 2026-06-14 | Donald Zurbay | Director | Other Derivative Acquisition | +2,383 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 02:49:39 · For reference only, not investment advice and not tailored to your situation.